| 9.88 -0.32 (-3.14%) | 07-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 12.77 | 1-year : | 14.92 |
| Resists | First : | 10.93 | Second : | 12.77 |
| Pivot price | 9.94  |
|||
| Supports | First : | 9.16 | Second : | 8.07 |
| MAs | MA(5) : | 10.24 |
MA(20) : | 9.75 |
| MA(100) : | 9.07 |
MA(250) : | 10.69  |
|
| MACD | MACD : | 0.3 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 55.4 |
D(3) : | 70.6 |
| RSI | RSI(14): 54.1 |
|||
| 52-week | High : | 16.44 | Low : | 6.23 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ OCUL ] has closed above bottom band by 43.8%. Bollinger Bands are 51.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 10.2 - 10.26 | 10.26 - 10.31 |
| Low: | 9.61 - 9.69 | 9.69 - 9.74 |
| Close: | 9.78 - 9.89 | 9.89 - 9.97 |
Ocular Therapeutix, Inc. is a biopharmaceutical company specializing in the creation, advancement, and commercialization of ophthalmic treatments. Their innovative approach leverages a proprietary bioresorbable hydrogel technology to address a range of eye diseases and conditions. The company currently offers two key products: ReSure Sealant, an ophthalmic device designed to prevent fluid leakage from corneal incisions after cataract surgery, and DEXTENZA, a dexamethasone-based ophthalmic insert used to manage post-surgical inflammation and pain in the eye, as well as to treat allergic conjunctivitis. In addition to their commercial offerings, Ocular Therapeutix is actively developing several product candidates in various clinical stages, including: OTX-TKI, an axitinib intravitreal implant in Phase 1 clinical trials for wet age-related macular degeneration (AMD) and other retinal diseases. OTX-TIC, a travoprost intracameral implant, currently in Phase 2 studies for open-angle glaucoma and ocular hypertension. OTX-CSI, a cyclosporine intracanalicular insert that has successfully completed Phase 2 clinical trials for dry eye disease. OTX-DED, a dexamethasone intracanalicular insert undergoing Phase 2 evaluation for the temporary relief of dry eye symptoms. Strategic partnerships are also a significant part of Ocular Therapeutix's operations. This includes a collaboration with Regeneron Pharmaceuticals, Inc. focused on developing and commercializing products that combine Ocular Therapeutix's sustained-release hydrogel technology with Regeneron's large molecule VEGF-targeting compounds for retinal disease treatment. Another partnership with AffaMed Therapeutics Limited covers the development and commercialization of DEXTENZA and OTX-TIC. Additionally, a discovery-focused collaboration with Mosaic Biosciences aims to pinpoint novel targets and therapeutic agents for dry age-related macular degeneration (dAMD). Established in 2006, Ocular Therapeutix, Inc. maintains its headquarters in Bedford, Massachusetts.
Fri, 10 Jul 2026
Does Ocular Therapeutix (OCUL) Joining Russell Value Indexes Quietly Recast Its Long‑Term Investor Base? - simplywall.st
Thu, 09 Jul 2026
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Wed, 08 Jul 2026
Ocular Therapeutix (OCUL) Joins Russell Value Indexes, Is The Stock Now Too Pricey? - Sahm
Wed, 01 Jul 2026
Ocular Therapeutix™ to Participate in July Scientific and Investor Conferences - GlobeNewswire
Thu, 25 Jun 2026
Is Ocular Therapeuticx, Inc. (OCUL) Stock Positioned for Growth After Positive FDA Feedback on Axpaxli? - Yahoo Finance
Tue, 19 May 2026
What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 219 (M) |
| Shares Float | 184 (M) |
| Held by Insiders | 0.9 (%) |
| Held by Institutions | 95.7 (%) |
| Shares Short | 26,700 (K) |
| Shares Short P.Month | 25,090 (K) |
| EPS | -1.4 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.66 |
| Profit Margin | 0 % |
| Operating Margin | -865.5 % |
| Return on Assets (ttm) | -32.9 % |
| Return on Equity (ttm) | -68.6 % |
| Qtrly Rev. Growth | 0.8 % |
| Gross Profit (p.s.) | -0.8 |
| Sales Per Share | 0.23 |
| EBITDA (p.s.) | -1.35 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -226 (M) |
| Levered Free Cash Flow | -149 (M) |
| PE Ratio | -7.06 |
| PEG Ratio | 0 |
| Price to Book value | 3.71 |
| Price to Sales | 41.57 |
| Price to Cash Flow | -9.57 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|